- Home
- RPD vs LENZ Comparison
RPD vs LENZ Comparison
Compare RPD & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPD
- LENZ
- Stock Information
- Founded
- RPD 2000
- LENZ 2019
- Country
- RPD United States
- LENZ United States
- Employees
- RPD N/A
- LENZ N/A
- Industry
- RPD Computer Software: Prepackaged Software
- LENZ Medicinal Chemicals and Botanical Products
- Sector
- RPD Technology
- LENZ Health Care
- Exchange
- RPD Nasdaq
- LENZ Nasdaq
- Market Cap
- RPD 881.4M
- LENZ 852.0M
- IPO Year
- RPD 2015
- LENZ 2021
- Fundamental
- Price
- RPD $15.67
- LENZ $30.73
- Analyst Decision
- RPD Hold
- LENZ Strong Buy
- Analyst Count
- RPD 21
- LENZ 4
- Target Price
- RPD $24.00
- LENZ $56.25
- AVG Volume (30 Days)
- RPD 1.4M
- LENZ 1.3M
- Earning Date
- RPD 11-04-2025
- LENZ 11-05-2025
- Dividend Yield
- RPD N/A
- LENZ N/A
- EPS Growth
- RPD N/A
- LENZ N/A
- EPS
- RPD 0.35
- LENZ N/A
- Revenue
- RPD $858,667,000.00
- LENZ $17,500,000.00
- Revenue This Year
- RPD $2.75
- LENZ N/A
- Revenue Next Year
- RPD $3.21
- LENZ $285.82
- P/E Ratio
- RPD $44.56
- LENZ N/A
- Revenue Growth
- RPD 3.08
- LENZ N/A
- 52 Week Low
- RPD $13.21
- LENZ $16.54
- 52 Week High
- RPD $44.47
- LENZ $50.40
- Technical
- Relative Strength Index (RSI)
- RPD 50.29
- LENZ 52.59
- Support Level
- RPD $13.41
- LENZ $27.44
- Resistance Level
- RPD $14.00
- LENZ $32.13
- Average True Range (ATR)
- RPD 0.50
- LENZ 2.23
- MACD
- RPD 0.27
- LENZ 1.13
- Stochastic Oscillator
- RPD 83.85
- LENZ 87.35
About RPD Rapid7 Inc.
Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.